A recent study by the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) group showed an incidence of EGFR-mutations of 27% in a large cohort of multi-treated recurrent/metastatic LACs [10], as opposed to the frequency of 11% reported in The Cancer Genome Atlas (TCGA) cohort, which mainly consisted of non-metastatic, surgically removed LACS that had not received systemic treatment [3]. The gene discussed is EGFR; the disease is cancer.